New Blood Tests Detect Cancer Early
What happened
Multi-cancer early detection blood tests are now hitting the market, promising to find cancers sooner. However, doctors are urging caution, pointing out that the efficacy of these tests has not yet been proven through the FDA approval process, creating a debate over their immediate clinical use.
Why it matters
The global market for multi-cancer early detection (MCED) tests was valued between $1.12 billion and $1.5 billion in 2024, with projections suggesting it could exceed $5.8 billion by 2034. This anticipated growth is fueled by advancements in genomic technologies and a rising demand for earlier, more effective cancer screening tools. Key companies competing in this space include GRAIL, Guardant Health, Exact Sciences Corporation, and Freenome Holdings. These firms are leveraging significant venture capital and research funding to conduct large-scale clinical trials aimed at validating their technologies and capturing market share. The technology behind these tests, often called a "liquid biopsy," analyzes a blood sample for signals of cancer, such as circulating tumor DNA (ctDNA). Using next-generation sequencing and machine learning, the tests can detect these signals and, in some cases, predict the cancer's origin in the body. Currently, no MCED test has received full FDA approval for cancer screening. However, some, like the Galleri test, are available to patients because they are regulated as Laboratory Developed Tests (LDTs) under the Clinical Laboratory Improvement Amendments (CLIA). In a significant move, GRAIL submitted a premarket approval application to the FDA for its Galleri test in early 2026. The submission includes data from extensive trials, such as a U.K. study with over 140,000 participants, and FDA approval is seen as a crucial step toward securing Medicare coverage. A primary concern for widespread adoption is the potential for both false-positive and false-negative results. A false positive can lead to unnecessary and invasive diagnostic procedures, while a false negative might delay the diagnosis of an actual cancer. Ongoing research aims to determine how these tests impact overall cancer mortality rates.
Key numbers
- The global market for multi-cancer early detection (MCED) tests was valued between $1.12 billion and $1.5 billion in 2024, with projections suggesting it could exceed $5.8 billion by 2034.
- In a significant move, GRAIL submitted a premarket approval application to the FDA for its Galleri test in early 2026.
- study with over 140,000 participants, and FDA approval is seen as a crucial step toward securing Medicare coverage.
What happens next
- The global market for multi-cancer early detection (MCED) tests was valued between $1.12 billion and $1.5 billion in 2024, with projections suggesting it could exceed $5.8 billion by 2034.
- Using next-generation sequencing and machine learning, the tests can detect these signals and, in some cases, predict the cancer's origin in the body.
- Ongoing research aims to determine how these tests impact overall cancer mortality rates.
Quick answers
What happened in New Blood Tests Detect Cancer Early?
Multi-cancer early detection blood tests are now hitting the market, promising to find cancers sooner. However, doctors are urging caution, pointing out that the efficacy of these tests has not yet been proven through the FDA approval process, creating a debate over their immediate clinical use.
Why does New Blood Tests Detect Cancer Early matter?
The global market for multi-cancer early detection (MCED) tests was valued between $1.12 billion and $1.5 billion in 2024, with projections suggesting it could exceed $5.8 billion by 2034. This anticipated growth is fueled by advancements in genomic technologies and a rising demand for earlier, more effective cancer screening tools. Key companies competing in this space include GRAIL, Guardant Health, Exact Sciences Corporation, and Freenome Holdings. These firms are leveraging significant venture capital and research funding to conduct large-scale clinical trials aimed at validating their technologies and capturing market share. The technology behind these tests, often called a "liquid biopsy," analyzes a blood sample for signals of cancer, such as circulating tumor DNA (ctDNA). Using next-generation sequencing and machine learning, the tests can detect these signals and, in some cases, predict the cancer's origin in the body. Currently, no MCED test has received full FDA approval for cancer screening. However, some, like the Galleri test, are available to patients because they are regulated as Laboratory Developed Tests (LDTs) under the Clinical Laboratory Improvement Amendments (CLIA). In a significant move, GRAIL submitted a premarket approval application to the FDA for its Galleri test in early 2026. The submission includes data from extensive trials, such as a U.K. study with over 140,000 participants, and FDA approval is seen as a crucial step toward securing Medicare coverage. A primary concern for widespread adoption is the potential for both false-positive and false-negative results. A false positive can lead to unnecessary and invasive diagnostic procedures, while a false negative might delay the diagnosis of an actual cancer. Ongoing research aims to determine how these tests impact overall cancer mortality rates.
